99 related articles for article (PubMed ID: 1748397)
21. Interleukin-8 in Hodgkin's disease. Preferential expression by reactive cells and association with neutrophil density.
Foss HD; Herbst H; Gottstein S; Demel G; Araujó I; Stein H
Am J Pathol; 1996 Apr; 148(4):1229-36. PubMed ID: 8644863
[TBL] [Abstract][Full Text] [Related]
22. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.
Weihrauch MR; Manzke O; Beyer M; Haverkamp H; Diehl V; Bohlen H; Wolf J; Schultze JL
Cancer Res; 2005 Jul; 65(13):5516-9. PubMed ID: 15994922
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of circulating ICAM-1 are increased in Hodgkin's disease.
Gruss HJ; Dölken G; Brach MA; Mertelsmann R; Herrmann F
Leukemia; 1993 Aug; 7(8):1245-9. PubMed ID: 8102418
[TBL] [Abstract][Full Text] [Related]
24. [Measurement of five cytokines in the serum of malignant lymphoma patients].
Zhu H; Wang Y; Han X
Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):85-8. PubMed ID: 10921109
[TBL] [Abstract][Full Text] [Related]
25. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
Gause A; Jung W; Schmits R; Tschiersch A; Scholz R; Pohl C; Hasenclever D; Diehl V; Pfreundschuh M
Ann Oncol; 1992 Sep; 3 Suppl 4():49-52. PubMed ID: 1333270
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C Virus and related changes in immunological parameters in non Hodgkin's lymphoma patients.
el-Din HM; Attia MA; Hamza MR; Khaled HM; Thoraya MA; Eisa SA
Egypt J Immunol; 2004; 11(1):55-64. PubMed ID: 15724387
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis.
Ohshima K; Akaiwa M; Umeshita R; Suzumiya J; Izuhara K; Kikuchi M
Histopathology; 2001 Apr; 38(4):368-75. PubMed ID: 11318902
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease.
Trümper L; Jung W; Dahl G; Diehl V; Gause A; Pfreundschuh M
Ann Oncol; 1994; 5 Suppl 1():93-6. PubMed ID: 8172827
[TBL] [Abstract][Full Text] [Related]
29. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.
Heuser C; Guhlke S; Matthies A; Bender H; Barth S; Diehl V; Abken H; Hombach A
Int J Cancer; 2004 Jun; 110(3):386-94. PubMed ID: 15095304
[TBL] [Abstract][Full Text] [Related]
30. Expression of Epstein-Barr virus latent gene products and related cellular activation and adhesion molecules in Hodgkin's disease and non-Hodgkin's lymphomas arising in patients without overt pre-existing immunodeficiency.
Kanavaros P; Jiwa M; van der Valk P; Walboomers J; Horstman A; Meijer CJ
Hum Pathol; 1993 Jul; 24(7):725-9. PubMed ID: 8100553
[TBL] [Abstract][Full Text] [Related]
31. Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases.
Foss HD; Herbst H; Oelmann E; Samol J; Grebe M; Blankenstein T; Matthes J; Qin ZH; Falini B; Pileri S
Br J Haematol; 1993 Aug; 84(4):627-35. PubMed ID: 8217820
[TBL] [Abstract][Full Text] [Related]
32. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells.
Kapp U; Yeh WC; Patterson B; Elia AJ; Kägi D; Ho A; Hessel A; Tipsword M; Williams A; Mirtsos C; Itie A; Moyle M; Mak TW
J Exp Med; 1999 Jun; 189(12):1939-46. PubMed ID: 10377189
[TBL] [Abstract][Full Text] [Related]
33. Expression of interleukin-2R alpha and interleukin-2R beta in Hodgkin's disease.
Tesch H; Günther A; Abts H; Jücker M; Klein S; Krueger GR; Diehl V
Am J Pathol; 1993 Jun; 142(6):1714-20. PubMed ID: 8506943
[TBL] [Abstract][Full Text] [Related]
34. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
35. [Plasma interleukin-6 and interleukin-10 levels in different subtypes of lymphoma and their clinical significance].
Wang X; Zhao HR; Gu X; Liu P; Bikmituofu H
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Aug; 31(8):1360-4. PubMed ID: 21868324
[TBL] [Abstract][Full Text] [Related]
36. Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value.
Uskudar Teke H; Gulbas Z; Bal C
J BUON; 2014; 19(1):191-7. PubMed ID: 24659663
[TBL] [Abstract][Full Text] [Related]
37. Hodgkin's Disease and Anaplastic Large Cell Lymphoma Revisited. 1. unique cytokine and cytokine receptor profile distinguished from that of non-hodgkin's lymphomas.
Hsu SM; Waldron J; Xie SS; Hsu PL
J Biomed Sci; 1995 Oct; 2(4):302-313. PubMed ID: 11725067
[TBL] [Abstract][Full Text] [Related]
38. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
Younes A; Pro B; Robertson MJ; Flinn IW; Romaguera JE; Hagemeister F; Dang NH; Fiumara P; Loyer EM; Cabanillas FF; McLaughlin PW; Rodriguez MA; Samaniego F
Clin Cancer Res; 2004 Aug; 10(16):5432-8. PubMed ID: 15328181
[TBL] [Abstract][Full Text] [Related]
39. Regulated plasma levels of colony-stimulating factors, interleukin-6 and interleukin-10 in patients with acute leukaemia and non-hodgkin's lymphoma undergoing cytoreductive chemotherapy.
Reisbach G; Kamp T; Welzl G; Geiz C; Abedinpour Fariborz ; Lodri A; Kaboth W; Dörmer P; Nerl C
Br J Haematol; 1996 Mar; 92(4):907-12. PubMed ID: 8616084
[TBL] [Abstract][Full Text] [Related]
40. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.
Biggar RJ; Johansen JS; Smedby KE; Rostgaard K; Chang ET; Adami HO; Glimelius B; Molin D; Hamilton-Dutoit S; Melbye M; Hjalgrim H
Clin Cancer Res; 2008 Nov; 14(21):6974-8. PubMed ID: 18980992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
